Tumor Targeting Services
-
based in USA
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. However, this paradigm is limited by the expression of tumor targets on healthy cells, resulting ...
-
Manufactured by Invicro, LLCbased in USA
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue. Streamlined development, evaluation and clinical ...
-
Manufactured by Inovotion Sasbased in FRANCE
Target validation is an essential and critical phase of the drug discovery process. This is a crucial step before starting to develop a treatment based on a targeted protein that has been identified to play a role in the disease. The target protein’s role must be clearly identified before starting to develop a drug candidate ...
-
by SonALAsensebased in USA
We are committed to providing hope in the face of despair with a unique proprietary non-invasive drug-device combination therapy, ALA Sonodynamic Therapy (SDT), for the treatment of recurrent glioblastoma multiforme (rGBM). ...
-
Manufactured by ITM Isotope Technologies Munich SEbased in GERMANY
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Once injected into the patient, the radiopharmaceutical finds its way to the tumor through the ...
-
based in UNITED KINGDOM
Viewing cancer through the immune lens (immuno-oncology) has led to the most promising advancements in cancer treatment in recent history, nonetheless the full potential of the approach is as yet ...
-
Manufactured by Immatics N.V.based in GERMANY
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
-
Manufactured by Immatics N.V.based in GERMANY
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
-
Manufactured by Invicro, LLCbased in USA
is a popular target for imaging to identify the presence of prostate cancer and to deliver drugs directly to the cancerous cells3. A PSMA-PET scan is a powerful molecular imaging technique that can accurately localize prostate cancer and assess the level of a tumor’s PSMA expression. There are currently two USFDA and one EMA-approved PSMA-PET ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you